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Chlamydia trachomatisBiobanks are invaluable resources in genomic research of both the infectious diseases and their hosts. This article
examines the role of biobanks in basic research of infectious disease genomics, as well as the relevance and ap-
plicability of biobanks in the translation of impending knowledge and the clinical uptake of knowledge of infec-
tious diseases. Our research identiﬁes potential ﬁelds of interaction between infectious disease genomics and
biobanks, in line with global trends in the integration of genome-based knowledge into clinical practice. It also
examines various networks and biobanks that specialize in infectious diseases (including HIV, HPV and Chlamyd-
ia trachomatis), and provides examples of successful research and clinical uptake stemming from these biobanks.
Finally, it outlines key issues with respect to data privacy in infectious disease genomics, as well as the utility of
adequately designed and maintained electronic health records. We maintain that the public should be able to
easily access a clear and detailed outline of regulations andprocedures for sample and data utilization by academ-
ic or commercial investigators, and also should be able to understand the precise roles of relevant governing bod-
ies. This would ultimately facilitate uptake by researchers and clinics. As a result of the efforts and resources
invested by several networks and consortia, there is an increasing awareness of the prospective uses of biobanks
in advancing infectious disease genomic research, diagnostics and their clinical management.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Over time, the deﬁnition of a “biobank” has moved away from an
early view of a biobank as population-based to include awider typology
of biobanks thatwe ﬁnd in the literature today. In a survey conducted in
2012, researchers involved in managing sample collections were asked
about their deﬁnition of biobanks. The results of the survey showed the
consensus among respondents that the term biobankmay be applied to
biological collections of human, animal, plant or microbial samples. Ad-
ditionally, the term biobank should only be applied to sample collec-
tions with associated sample data, and to collections that are managed
according to professional standards (Hewitt and Watson, 2013).
In post-Human Genome Project research, the role of biobanking as
a component of research infrastructure is broadening, as knowledgelth Genomics, Department of
W (School for Oncology &
& Life Sciences, University of
NS.50-H1.330, Maastricht, The
ré).
pen access article under the CC BY-Nfrom biobanks contributed to the understanding of the etiology of mul-
tifactorial diseases caused by both mutations in a variety of genes and
the inﬂuence of environmental factors and lifestyle (Brand and
Probst-Hensch, 2007; Knoppers et al., 2012). Furthermore, biobanks
have paved the way for the evolution of personalized medicine, espe-
cially the development of “tailored” drugs (Gottweis and Zatloukal,
2007). In recent years, integration, analysis and interpretation of data
originating from biobanks have begun to play a growing role in our un-
derstanding of genetic susceptibilities of infectious diseases. The actual-
ity of infectious diseases and the perpetual challenge they pose for
researchers and physicians are reﬂected in both the high prevalence
and the high mortality of existing and growing incidence of emerging
infectious diseases (Jones et al., 2008). In fact, infectious diseases repre-
sent a major health threat worldwide, and are a particularly signiﬁcant
burden to developing countries (Frodsham and Hill, 2004).
The importance of genetic factors in the pathogenesis of infectious
diseases has transformed our understanding of such diseases by incor-
porating host genetic determinants that modulate immune responses
as factors of pathogenesis. We now understand that host responses
can determine the outcome of an infection as much as – if not more
than – theproperties of the pathogen itself (Peng et al., 2009). Genomics
outlinedmolecular biomarkers and pathways as targets for diagnosis orC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tween genetic factors and susceptibility to the course and the outcome
of infectious diseases are predominantly studied through candidate
genes, genomewide associations, and twin studies (Hill, 2001). This re-
search means that biobanks (especially large international networks of
biobanks driven by the needs of researchers, who require large collec-
tions of samples) are an imperative infrastructure for research in host
genomics (Meijer et al., 2012).
According to Gotweiss and Zatloukal (Gottweis and Zatloukal,
2007), there are four main types of biobanks:
(1) clinical case/control biobanks, which contain biological samples
taken from patients with speciﬁc diseases and from healthy con-
trol patients
(2) population-based biobanks, which contain samples from smaller
or larger subsets of a population with or without a certain dis-
ease;
(3) population isolate biobanks, which contain homogenous genetic
material of the population represented; and
(4) twin registries, which contain samples frommonozygotic and di-
zygotic twins.
Biobanks contain both samples and data; this twofold nature is the
root of much of the legal and ethical controversy surrounding biobanks
today. Issues concerning privacy health-related information, informed
consent, secondary use of samples, and harmonization of legislation
and networking of biobanks are often researched in conjunction with
the term “biobanking” (Townend, 2012). The potential impact of
biobank-generated knowledge (and its becoming an integral part of
public health policies) on our understanding of the etiology of disease,
on improving diagnosis and treatment, and ultimately on the health of
individuals and populations as a whole has been largely ignored thus
far (Knoppers et al., 2012).
Uses of biobanks for public health are (Brand and Probst-Hensch,
2007):
• timely, responsible and effective integration of genome-based health
technologies and information into health research, policy and prac-
tice;
• supporting the translational process from basic knowledge generated
in existing biobanks to the development and implementation of
health policies, interventions and programs;
• recognizing the multi-tasking nature of biobanks in the accommoda-
tion of different needs by enhancing the ability of biobanks to serve re-
searchers and other relevant stakeholders with particular public
health perspectives.
In 1990, Lee identiﬁed what he considered to be the ideal properties
of a biospecimen bank: a secure, ongoing source of funding; a cryogenic
storage facility; selection criteria for obtaining and keeping the best
samples in storage; and ensuring the continuation of research to opti-
mize the collection and handling of samples (Lee, 1990). De Paoli (De
Paoli, 2005) also identiﬁed what he considered to be the main roles of
biobanking in microbiology research:
- to enable unfettered epidemiological research: prospective use of
biobanking is key to detecting and tracking different strains, com-
paring new strains with previously stored ones, determining
modes of transmission, and ultimately combating infections
- to ensure progress in diagnostics: by comparing samples taken from
the same subjects over time or by comparing samples taken from
different subjects at the same point in time, or by applying novel di-
agnostic tools to the analysis of samples that exhibit increased sensi-
tivity and speciﬁcity.
- tomanage studieswith large sample sizes: thismay refer to research
with sample collections coming from different geographical loca-
tions, or research that is conducted in several remote laboratories.
- to establish biorepositories with characterized host cell lines: celllines can be used for research, diagnostics and quality control, and
other scientiﬁc pursuits.
- to assist in building a microbial tree of life: such biobanks provide
the basis for mapping out microbial diversity and evolution. Given
the increasingly imminent threat that emerging highly virulent or
therapy-resistant strains pose for global health, the importance of
these types of biobank collections will likely rise in the near future.
In addition to these roles, biobanks can serve as the foundation for
conducting research in host genomics and other ‘omic’ sciences, eluci-
dating the role and interactions of the host's immunogenetic factors in
infections (Ballana et al., 2012), aswell as driving prospective diagnostic
and therapeutic advances (Haralambieva and Poland, 2010).
This article examines the role of biobanks in the basic research in
infectious disease genomics, and also observes the relevance and appli-
cability of biobanks in both the translation of impending knowledge and
the clinical uptake of biobank-generated knowledge in infectious
diseases. Our research identiﬁes potential ﬁelds of interaction between
infectious disease genomics and biobanks, in line with the global trend
of integration of genome-based knowledge into clinical practice.
2. Materials and methods
A literature search was performed on the identiﬁcation of the
existing links between biobanking and infectious diseases; on points
of potential collaboration between biobanks, clinics and surveillance
agencies; and on the examination of the relevance of electronic health
records (EHR) in genomic research of infectious diseases. The study fo-
cused on examples of the translation of biobank-generated genome-
based knowledge to everyday clinical practice. Databases (PubMed,
Cochrane library, Google Scholar), electronic journal collections
(Maastricht University EJ collection) and the websites of relevant orga-
nizations, networks and consortia (OECD, EAPM, P3G, BBMRI) were
searched for appropriate references. The terms used in the searches
were [“biobank*” AND (“infectious disease*” OR “genomic*”)]. Re-
trieved articles were further selected based on relevance. Additional
search terms were “public health”, “data management” and “data
privacy”.
This article provides examples of existing biobanks with substantial
resources for infectious disease research, such as those for human
immunodeﬁciency virus (HIV), Human papillomavirus (HPV), and
Chlamydia trachomatis (CT).
3. Results
3.1. Human versus microbial sample biobanks
There is an obvious delineation between samples taken from human
individuals suffering from a pathological condition related to an infec-
tion (whomay or may not be infected with or are carriers of the patho-
gen) and samples of the infectious agent itself. The former is primarily
relevant to host ‘omic’ research, as it provides the material basis for
both candidate gene/SNP-approaches and genome-wide association re-
search in seeking (co)morbidity associations, and also investigates the
pathogen interactions with host proteomes (Zhang et al., 2010). These
samples should be pairedwith relevant categories of patient phenotypic
data. Pathogen samples enable epidemiological studies, investigate
genetic strains of that species, and develop better diagnostic tools and
novel therapies (De Paoli, 2005). Biomaterial samples may differ in pro-
cessing and storage, aswell as in shelf-life. As biomedical sciencemoves
away from the deconstruction of living systems and turns towards a
more integrative, all-encompassing approach (through the likes of sys-
tems biology) (Khoury et al., 2007), it is reasonable to expect that re-
searchers increasingly begin to assess host ‘omic’ data together with
infectious agents ‘omic’ proﬁles. As a prerequisite, adequate samples
should always be accompanied by relevant data.
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Advances in sequencing technologies have resulted in a relentless
inﬂux of data that need to be interpreted. Currently, researchers are
generating datamore rapidly than can be analyzed. In particular, the ge-
netic variability of bacteria accumulated through evolution is enormous
and signiﬁcantly increases the volume of datasets. Public health geno-
mics speciﬁcally emphasizes the need to examine all ‘omics’ (Khoury
et al., 2007; Mardis, 2009), which, in the case of infectious disease,
involves both the host and the pathogen. This emphasis dramatically
increases demand for the effective deciphering of large amounts of
data. There are, however, efforts among members of the microbiology
community to develop strategies that would make this data manage-
able. For example, by grouping select loci of the pathogenic bacterial
strain into schemes (the so-called gene-by-gene approach) and
by implementing themes schemes in conjunction with conventional
(sequence-based) schemes in adequate database platforms, data that
is obtained through different studies and can be used more effectively
in combined analyses (Maiden et al., 2013). In thisway, “genotype sum-
maries” of selected genes could be linked to phylogenetic relationships
and functional characteristics of bacteria, thereby helping researchers
navigate vast bacterial genomic diversity.
3.3. Existing infectious disease biobanks and networks
The number of laboratories that are creating their own biobanks is
difﬁcult to quantify with full precision. However, the number of organi-
zations that are developingnation-wide or transnational collections and
are building large consortia and networks is ever increasing (De Paoli,
2005). Large networks such as the Public Population Project in Geno-
mics and Society (P3G) (http://p3g.org/) and Biobanking and Biomolec-
ular Resources Research Infrastructure (BBMRI) (http://bbmri.eu/) are
changing the landscape of international collaboration in biobanking,
harmonizing regulatory legislation and thus facilitating the use of
biobanks in research (Wichmann et al., 2011). Promising nation-wide
models have also emerged, including the United Kingdom Biobank
(http://www.ukbiobank.ac.uk/), the Swedish National Biobank pro-
gramme (now the Swedish arm of BBMRI, http://www.bbmri.se/), the
Iceland Biobank, and others. Some biobanks, however, are not posi-
tioned as public domain entities; in the case of Iceland, for example,
the biobank is a private company that has been given a commercial
data license (Mitchell, 2010).
This article presents several infectious disease biobanks and their ef-
fective usage, which has led to cases of successful clinical uptake (or its
near-future prospects) for HIV, CT and HPV (for which there is a more
substantial body of literature available). These biobanks are founded
and governed by hospitals and academic institutions and provide clear
examples of how biobanking can stimulate research in infectious dis-
ease genomics.
3.3.1. HIV
The Infectious Diseases Biobank (IDB) at King's College London is an
oft-cited example of an infectious disease-oriented biobank (Kozlakidis
et al., 2012; Towie, 2007; Williams et al., 2009). The IDB is actively
collecting samples from patients infected with HIV, hepatitis B and C
viruses, and invasive bacteraemias (such as the methicillin resistant
Staphylococcus aureus (MRSA)). The IDB is also collecting samples
from healthy control subjects. The number of HIV patients with
archived materials in the IDB is steadily increasing, resulting in the
availability of distinct patient cohorts (in meaningful numbers) to re-
searchers. Data on the IDB's website indicate that by September 2010,
HIV sample donations had reached 500 annually. Examples of research
stemming from this collection are (as stated on the IDB website): the
roles of vpu gene and tetherin in HIV/AIDS pathogenesis; gene expres-
sion signatures in in vivo and in vitro HIV-1 infection; non-infectious
HIV co-morbidities; renal function and bone homeostasis in patientson HAART; the deﬁnition of CD161+ CD8+ T cell subset function in
HIV infection and their response to therapy; the effect of Maraviroc on
microbial translocation inHIV infected individuals receiving antiretrovi-
ral therapy; and the metabolic impact of Darunavir/ritonavir mainte-
nance monotherapy after successful viral suppression with standard
Atripla in HIV-1-infected patients. Aside from archiving biological
samples, the BioBank runs a database in which the following clinical in-
formation on HIV donors is archived: histories of CD4+ cell numbers
and plasma viral loads; last knownHIV negative result and ﬁrst positive
HIV test; birth date; ethnicity; gender; HAART administering; and other
complications. The database also features sample processing informa-
tion (dates and times of venepuncture, processing and freezing); and
details on aliquots that have been stored or transferred to researchers.
Another example of an infectious disease-oriented biobank is the
SpanishHIV BioBank (Garcia-Merino et al., 2009). The primary objective
of this biobank is to further scientiﬁc knowledge about HIV infection by
providing biological samples fromHIV-infected patients that are includ-
ed in cohorts for the objective of carrying out research. The HIV BioBank
receives samples from 28 hospitals, spread across Spain, which are
grouped into 6 cohorts of HIV-patients, each with deﬁned characteris-
tics. Anymember of the AIDSNetwork, or any party to a relevant collab-
oration with a member can apply for samples. Sample release
applications are evaluated by members of the Scientiﬁc Committee. If
the project is approved, the researcher signs a Release Agreement
with the director of the BioBank andwith the coordinator of the Cohort.
The BioBank and the Cohort are responsible for locating the type and
number of samples needed to carry out the project. Once a year, after
the samples have been released, the principal researcher sends a scien-
tiﬁc report to the BioBank containing his or her results, such that the
BioBank can maintain up-to-date records on all projects.
3.3.2. Chlamydia trachomatis
Partners of the EpiGenChlamydia Consortium (urogenital and ocular
CT infections), coordinated by the London School of Hygiene and Trop-
ical Medicine (by David Mabey and Robin Bailey and their Gambian
partners) who are researching ocular Chlamydia-related conditions,
have already deﬁned and secured 1500 case–control pairs (n =
3000). More than 4000 specimens that are currently in use have
been collected by Dutch partners, and 10,000 specimens are avail-
able for further studies (Morre et al., 2009). One goal was to build a
biobank and data warehouse—a biomedical, ethically-developed
and run central sample collection and data management system.
The Consortium is investigating possibilities for conducting genetic
and epidemiologic Chlamydia research with samples from existing
biobanks in Northern European countries.
The Consortium also aims to structure trans-national research to
such a degree that comparative genomics and genetic epidemiology
can be performed on large numbers of unrelated individuals. The most
pivotal deliverables of this project were biobanking and data-
warehouse building. These deliverableswill allow for continuous gener-
ation of scientiﬁc knowledge on CT–host interaction genetic predisposi-
tion to CT infection, and the development of tools for early detection of
this predisposition. The study of sequence variation (mainly SNPs) is a
technique employed by different consortium partners to gain insight
into the differences in clinical courses of infection, in order to identify
genetic markers for susceptibility.
A review byMalogajski et al. (Malogajski et al., 2013) gives an over-
view of immunogenetic factors that have a demonstrable effect on
human susceptibility to and the severity of CT. These immunogenetic
factors are alleles (determined by speciﬁc SNPs) of pathogen recogni-
tion receptor genes. Women carrying one or a combination of these
alleles are at higher risk of contracting CT, or are at signiﬁcantly higher
risk of developing subfertility-related complications, such as tubal pa-
thology. The review proposes the development of novel diagnostic
tools for assessing individual risk faced by CT-positive women. Current-
ly, clinicians employ CT IgG serologywhen assessing these risks (Broeze
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predictive value of this serology is weak, and as a result, many physi-
cians recommend that women undergo additional invasive, stressful,
and costly diagnostic procedures. It is estimated that 40–45% of
women undergoing laparoscopy do not have tubal pathology. Addition-
ally, false negative serology results account for about 20% of women
whose tubal pathology will not be properly and timely diagnosed
(Lal et al., 2013). The proposed tool would introduce a diagnostic ap-
proach based on a combination of two factors: a predictive SNP load;
and serological markers for CT infection. On-going research aims to val-
idate this set of SNPs and a subsequent cut-off score for diagnostic pur-
pose. This tool would be the ﬁrst to use a genetic trait in the diagnosis of
infectious diseases severity in the triage of women.
3.3.3. HPV
Similar to the translation of CT biobank-derived data into diagnostic
applications for subfertility, the translation of HPV research results
should contribute to better diagnostics of cervical cancer and its pre-
neoplastic stages, cervical intraepithelial neoplasia (Malogajski et al.,
2013). Large biobanks and patient cohorts are used to achieve this re-
sult. Despite the anticipated outcomes of HPV vaccination (which
should lead to a drop in cervical cancer incidence in a matter of
decades), the needs of generations of women who were above the age
of expected exposure to HPV virus (andwere therefore left out of vacci-
nation programs) ought to be addressed. The cervical scraping
cytomorphology assessment, better known as the PAP test, is routinely
used throughout the world as a screening tool for cervical lesions; how-
ever, the PAP has low sensitivity. The introduction of high-risk HPV
(hrHPV) assessment will increase sensitivity and ease (especially in
the case of self-collected vaginal swabs) to determine a woman's risk
of developing cervical cancer. Referral to a gynecologist is only needed
where a woman is found to be infected by a hrHPV type. Some authors
propose the development of a triage tool for high-risk HPV positive
women based on methylation markers; this means that a woman
should only be referred for further examination if she tested positive
for one ormore hrHPV types and at the same time carries a combination
of methylation markers indicative of a progression of pre-neoplastic
stages. This approach builds upon a number of studies that show how
epigenetic alterations become increasingly presentwith each successive
stage of cervical lesion and cervical cancer, mainly in genes that are
important to the progression of cancer (e.g. tumor suppressors and
cell adhesion molecules), or genes coding microRNAs, whose role is to
bind to the viral nucleic sequences, thereby making them inaccessible
to enzymes that are replicating or transcribing. Based on the available
studies at that time, the review (Malogajski et al., 2013) highlighted
methylation patterns in MAL and CADM1 genes as optimal markers
for the development of a potential triage test (Overmeer et al., 2011).
A more recent review by Litjens et al. (2013) reached the same conclu-
sion, but added p16INK-4a/Ki-67 dual immunostaining and viral integra-
tion to the proposed set of markers.
3.4. Relevance of electronic health records
The rise in usage – and usability – of electronic health records (EHRs)
is a demonstrably promising catalyst in the efforts to better utilize and
standardize biobanks (Kohane, 2011). This pertains to handling the in-
formation on the biomaterial from the large cohort studies on a plethora
of diseases, including infectious diseases. ‘EHR-driven genomic
research’ can ideally be achieved using two distinct workﬂows. Firstly,
patients with a particular infectious disease or related sequelae could
be selected from the EHR by using language processing tools, such as
natural language processing (NLP) tools. In this case, the selected popu-
lation could thereupon be recruited, either for the purpose of providing
samples for genomic research, or in order to verify whether residual
samples taken on previous occasions could be utilized. Secondly, EHRs
can be used to broaden and advance clinical characterization by addingnew relevant data to the ﬁles of those individuals whose samples are
already stored in another biobank or have been used in the context of
a cohort study (Kohane, 2011). Electronic systems for the automated
detection of notiﬁable diseases have, in fact, been tested using EHRs.
In past decades, the term of preference was electronic medical records
(EMRs). This term has gradually been overtaken by the previouslymen-
tioned EHRs, as focus slowly expanded from the inclusion of basic clin-
ical patient data to the provision of a more complete insight into their
health background and care.
The so-called ESP (Electronic Medical Record Support for Public
Health) algorithmic system, which has been tested on Chlamydia re-
cords and others, assists not only in the identiﬁcation and reporting of
cases of notiﬁable disease, but also in the advancement of public health.
Prospective applications of EHRs include syndromic surveillance;
clinical decision support; the construction of vaccine registries; and
the assessment of areas with higher prevalence of disease (Klompas
et al., 2007). The incorporation of patient genome-based information
into EHRs would act as a major driving force for genomic medicine. It
would enable the investigation of potential comorbidities of genomic
associations (Kohane, 2011), and would elucidate the ways in which
such associations can individually or synergistically result in increased
susceptibility to or severity of infectious disease. That said, the incorpo-
ration of patient genome information into EHRs has thus far been a
daunting task, since most EHR systems are not designed to include ge-
nomic data (Kullo et al., 2013). Although the linear DNA sequence is
simple by nature, the sheer volume of data and the complexity of rela-
tions among the ‘functional components’ of DNA are signiﬁcant hurdles
in attempting to devise an EHR system using this information (Kullo
et al., 2013; Masys et al., 2012).
3.5. Data privacy and infectious disease genomics
While the issues of data privacy and consent exceed the parameters
of this article, we will brieﬂy lay out the state of the art in this ﬁeld, as
well as how legal frameworks, governance of infectious disease
biobanks and the handling of sensitive data can affect not only patient
rights, but also biomedical research generally. In 2013, during the Irish
presidency of the EU Council, the European Alliance for Personalised
Medicine (EAPM) hosted a conference on innovation and patient access
to personalized medicine, in which experts discussed recent advances
in healthcare and formulated conclusions relating to these advances
(EAPM, 2013). In order to optimize data security and to facilitate access
and consent (which would allow for re-use and secondary use of data),
it was concluded that robust legal regulation of personal data in scientif-
ic research should be implemented. Moreover, cross-border transfers of
data for the purposes of scientiﬁc research should be stimulated in cases
where such privacy instruments have been deployed. It is important to
note that, in harmonizing different systems of governance, a balance
must always be struck between the stimulation of cross-border trans-
fers of data and individual rights to privacy.
The importance of data protection cannot be underestimated,
especially in the handling of samples taken from individuals who are
afﬂicted with serious infections. Genomic discoveries concerning such
infections potentially create various forms of discrimination in the
context of future discovery. For example, research has shown that
African–American carriers of a polymorphism conferring a Duffy
antigen-negative phenotype, DARC -46C/C, are resistant to malaria
(Plasmodium vivax infection). However, subsequent research into this
polymorphism also revealed that carriers have a 40% increased likeli-
hood of becoming infected with the HIV-1 virus (He et al., 2008). In
this case, contrary to the protective character of CCR5- Δ32 deletion as
witnessed in European populations, the disruption of the expression
of a functional receptor is amajor disadvantage to the carrier. Evidently,
the risks of stigmatization and discrimination arising from genome-
based information (the disclosure of a patient's illness or infection sta-
tus being a potential infringement of patient rights) cannot be ignored.
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be achieved by developing trust between researchers and the public,
and by promoting the equal treatment of health research data (includ-
ing genome-based information) and the removal of silos for single-use
data. Since this information is theoretically unlimited in terms of lon-
gevity, robust data protection mechanisms must be in place for periods
longer than the samples' shelf-life (Heeney et al., 2011).
At the same time, different sets ofmechanisms are needed in parallel
with vigilant data protection. Genome-based research necessitates large
sample sizes in order to arrive at more reliable results; as a result,
overly-restrictive data protection policies can impede research and in-
novation (Masys et al., 2012). A large number of samples is necessary
to identify patient subgroups of interest. There are also calls for the pro-
vision of research data to the general public, particularly in cases where
the research itself was funded using taxpayer dollars (Church et al.,
2009). Entire human genome sequences, including those of several
prominent researchers, have already beenmade available to the general
public online (open access model). In spite of this open access, the de-
bate over balancing the right to consent versus the right to privacy is
far from resolved. The fact that fewer than 13–15 genomic locations
with variable repeats (or 30–80 statistically independent SNPs) can be
used to identify any one individual (Lin et al., 2004)puts requests for
the deregulation of data sharing into a new perspective. Samples that
contain a ‘genomic ﬁngerprint’ in combination with data relating to
the presence of serious infections pose a new threat to those safeguards
that ensure participant anonymity and prevent partial treatment. Due
to lack of funding, many academic institutions allow private organiza-
tions to handle their genomic databases; as a result, the protection of
the rights of humanparticipantsmay be at risk in any future commercial
uses of data (De Paoli, 2005).
4. Discussion
The aim of this reviewwas to explore empirical evidence on the role
of biobanking in infectious disease genomics and to outline the perti-
nent issues in setting up and utilizing biobank materials. We note that
published material that provides a detailed overview of existing infec-
tious disease biobanks and their uses to date is lacking. In order to facil-
itate extensive collaboration with researchers and to ensure the
continuation of research on infection, infectious disease biobanks must
become more visible, and must emphasize their societal impact. Thus
far, the authors have encountered underrepresentation of infectious
disease biobanks in publications and insufﬁcient information on ofﬁcial
websites. The public should be able to easily access a clear, detailed out-
line of regulations and procedures for sample and data utilization by
academic or commercial investigators, as well as an account of the pre-
cise roles of governing bodies. Examples of procedural transparency and
extensive online visibility include the King's College Infectious Disease
BioBank and the Spanish HIV BioBank (Garcia-Merino et al., 2009;
Williams et al., 2009). Appropriate regulation should precede the effec-
tive translation of biobank-based research to clinical settings; such reg-
ulation necessitates intensive efforts, so as to ensure rapid clinical
uptake.
In recent years, several biobanking consortia and extensive networks
have been formed, and there has been a visible increase in efforts, stake-
holders' involvement and resources allocated (Wichmann et al., 2011).
Nevertheless, infectious disease biobanks have yet to achieve their full
potential. This review does, however, provide several examples of
biobanks that have successfully contributed to the translation of data to
clinics and patients. In order to successfully utilize biobank information
in research on infectious disease, and in order to develop ‘tailored’ ther-
apies based on pharmacogenomics research, adequate representation of
ethnic minorities and neglected populations in biobanking is of para-
mount importance. Biobanks must be constructed to account for ethnic
differences in susceptibility to certain infectious diseases, which them-
selves have been extensively documented (Dolo et al., 2005; Velezet al., 2010). In HIV-AIDS therapy research, for example, extrapolations
of potential clinical implications of allele frequency differences between
different ethnicities could signiﬁcantly assist doctors when prescribing
therapies. Consortium for the BioBank and Pharmacogenetics database
of African populations is an example of efforts paving the way for indi-
vidualized treatments for HIV-AIDS (Matimba et al., 2008). The
Consortium's biobank of anonymous samples was used to determine
baseline frequency distribution of SNPs of genes affecting drug metabo-
lism; this usage enabled the establishment of a pharmacogenetics data-
base. Certain information can be essential for optimizing therapeutic
approaches and reducing ethnic-speciﬁc adverse reactions, such as the
different drug-metabolizing capacities of particular allelic versions of
enzymes (for instance CYP2B6⁎6 allele) (Matimba et al., 2008). There is
an argument to be made, however, that these differences are neither in-
herent nor applicable to all infections. Some authors argue, in terms of
decreased precision of data analysis, against 'blind social inclusivity’ in
biobank sampling at the potential expense of ‘analytical acuity.’ (Smart
et al., 2008). In countries such as the UK or the US, acting more fervently
upon the two aforementioned views could lead to a reevaluation of the
manner in which biobanks are governed.
EHR systemdesigners need to be encouraged to conﬁgure these sys-
tems so as to enable the incorporation of genome-based (or ‘omic’-
based) information. The addition of pathogen ‘omic’ data to an accom-
panying registry should be made feasible in order to promote research
in infectious diseases. Other forms of research, the clinical uptake of
genome-based knowledge, and the advancement of personalized med-
icine can all invaluably beneﬁt from a shifting approach to health record
management. Several approaches have been proposed to this effect, and
each acknowledges the unique nature of genomic data (Jing et al., 2012;
Masys et al., 2012).
The unique challenges associated with biobank-based research indi-
cate that it is in some aspects more complex than other types of health
or biomedical research. One of themain obstacles to translating biobank
data into the clinical setting is conﬁdentiality and privacy, which stem
from a necessary pairing of biobank information with personal and un-
related types of health information. The protection of data obtained
from samples of patients who are afﬂicted with serious infections is of
particular importance due to the potential in such cases for discrimina-
tion. Discrimination can result both from current interpretations of data,
and from future research and upcoming innovations in genomic
technologies.
4.1. Conclusions
A clear overview of the usage of existing infectious disease biobanks
is lacking in present literature, and we maintain that this information
should be readily accessible to the public, along with clear regulatory
and procedural guidelines for utilization of samples and data. This
would ultimately facilitate the currently insufﬁcient uptake by re-
searchers and clinics. Several biobanks have, however, already set high
standards in terms of instating appropriate regulation aswell as enabling
successful translation into clinical setting and can therefore serve as a
model to other biobanks. In recent years, efforts and resources that
have been invested in biobanking networks and consortia have surged.
As a result, there is a higher awareness of the multitude of ways in
which biobanking can advance basic research, diagnostics and – most
importantly – the clinical management of infectious disease. These
advances will ensure that research in biobank-based infectious disease
continues to progress.
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